GCPII reveals glutamate carboxypeptidase activity that is responsible for uptake of folate by intestine, moreover, it participates on regulation of neurotransmission via hydrolysis of the neuropeptide N-acetyl-aspartyl-glutamate in central nervous system.
| Institute |
|---|
| Institute of Biotechnology CAS |
| Cat. #: | 157667 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Metabolism |
| Application: | ELISA ; IHC ; WB |
| Target: | human glutamate carboxypeptidase II (amino acids 21-288) |
| Reactivity: | Human |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Glutamate carboxypeptidase II; NAALADase; FOLH1; PSMA; Folate Hydrolase 1; N-Acetylated Alpha-Linked Acidic Dipeptidase 1; Prostate Specific Membrane Antigen; ;PSMA; GCPII |
|---|---|
| Product description: | GCPII reveals glutamate carboxypeptidase activity that is responsible for uptake of folate by intestine, moreover, it participates on regulation of neurotransmission via hydrolysis of the neuropeptide N-acetyl-aspartyl-glutamate in central nervous system. GCPII is expressed in several tissues including prostate epithelium, kidney, small intestine and nervous system. Disregulation of GCPII activity could be connected with hyperhomocysteinemia and various neuro-pathological conditions including glutamate excitotoxicity. GCPII stays as a leading biomarker of prostate cancer due to huge upregulation of its expression in tumor tissue. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | human GCPII extracellular domain |
| Immunogen Uniprot ID: | Q04609 |
| Target background: | GCPII reveals glutamate carboxypeptidase activity that is responsible for uptake of folate by intestine, moreover, it participates on regulation of neurotransmission via hydrolysis of the neuropeptide N-acetyl-aspartyl-glutamate in central nervous system. GCPII is expressed in several tissues including prostate epithelium, kidney, small intestine and nervous system. Disregulation of GCPII activity could be connected with hyperhomocysteinemia and various neuro-pathological conditions including glutamate excitotoxicity. GCPII stays as a leading biomarker of prostate cancer due to huge upregulation of its expression in tumor tissue. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Novkov et al. 2017. Prostate. 77(7):749-764. PMID: 28247415. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.